论文部分内容阅读
目的观察重组人促红素联合左卡尼汀注射液治疗肾性贫血的临床疗效。方法将54例维持性血液透析的慢性肾衰肾贫血病人随机分为观察组和对照组。观察组采用重组人促红素联合左卡尼汀注射液进行治疗,对照组仅用重组人促红素进行治疗,对比两组的治疗效果。结果治疗后,两组患者的RBC、Hct和Hb都有明显的升高(P<0.05);治疗后观察组的RBC、Hct、Hb水平明显优于对照组(P<0.05);观察组患者每周平均重组人促红素用量少于对照组(P<0.05)。结论在重组人促红素的基础上联合左卡尼汀注射液能明显提高对肾性贫血的疗效,并减少并发症发生,值得临床推广。
Objective To observe the clinical efficacy of recombinant human erythropoietin combined with levocarnitine injection in the treatment of renal anemia. Methods 54 cases of chronic renal failure patients with hemodialysis renal anemia were randomly divided into observation group and control group. The observation group was treated with recombinant human erythropoietin combined with levocarnitine injection, while the control group was treated with recombinant human erythropoietin alone. The therapeutic effect was compared between the two groups. Results After treatment, the RBC, Hct and Hb in both groups were significantly increased (P <0.05). The levels of RBC, Hct and Hb in the observation group were significantly better than those in the control group (P <0.05) The average weekly amount of recombinant human erythropoietin was less than that of the control group (P <0.05). Conclusions The combination of levocarnitine and recombinant human erythropoietin can significantly improve the therapeutic effect on renal anemia and reduce the occurrence of complications, which is worthy of clinical promotion.